Marek Trněný

38PUBLICATIONS
316CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Jul 16, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.

|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Jul 13, 2026
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

|Jun 23, 2026
Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.

|Jun 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

|Apr 30, 2026
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Pageof 7

Frequent Collaborators

7 joint publications

Pier Luigi Zinzani

6 joint publications

Christopher R Flowers

5 joint publications

Franck Morschhauser

4 joint publications

Umberto Vitolo